Display options
Cite
Hashemian SJ, Rismanchi M, Esfahani EN, et al. Effect of calcitriol supplementation and tail suspension on serum biomarkers of bone formation in rats. J Diabetes Metab Disord. 2015;14:14doi: 10.1186/s40200-015-0142-5.
Hashemian, S. J., Rismanchi, M., Esfahani, E. N., Khoshvaghti, A., & Razi, F. (2015). Effect of calcitriol supplementation and tail suspension on serum biomarkers of bone formation in rats. Journal of diabetes and metabolic disorders, 1414. https://doi.org/10.1186/s40200-015-0142-5
Hashemian, Seyed Jafar, et al. "Effect of calcitriol supplementation and tail suspension on serum biomarkers of bone formation in rats." Journal of diabetes and metabolic disorders vol. 14 (2015): 14. doi: https://doi.org/10.1186/s40200-015-0142-5
Hashemian SJ, Rismanchi M, Esfahani EN, Khoshvaghti A, Razi F. Effect of calcitriol supplementation and tail suspension on serum biomarkers of bone formation in rats. J Diabetes Metab Disord. 2015 Mar 19;14:14. doi: 10.1186/s40200-015-0142-5. eCollection 2015. PMID: 25806360; PMCID: PMC4371718.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Metab Disord. 2015 Mar 19;14:14. doi: 10.1186/s40200-015-0142-5. eCollection 2015.

Effect of calcitriol supplementation and tail suspension on serum biomarkers of bone formation in rats.

Journal of diabetes and metabolic disorders

Seyed Jafar Hashemian, Mojtaba Rismanchi, Ensiyeh Nasli Esfahani, Amir Khoshvaghti, Farideh Razi

Affiliations

  1. Diabetes Research Center, Endocrinology and Metabolism Clinical Science Institute, Tehran University of Medical Sciences, Tehran, Iran.
  2. Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.
  3. Faculty of Aerospace and Sub-Aquatic Medicine, AJA University of Medical Sciences, Tehran, Iran.

PMID: 25806360 PMCID: PMC4371718 DOI: 10.1186/s40200-015-0142-5

Abstract

BACKGROUND: Calcitriol is documented to cause significant increase in bone mass densitometry counteracting osteoporosis. Promising results of calcitriol supplementation in studies aiming space flight induced osteoporosis is little and the effect of this hormone on biomarkers of bone metabolism is not examined yet in space flight models of osteoporosis in rats.

METHODS: This was an interventional animal study being performed in a 1-month period. We included 21 Sprague Dawley strain rats (>200 gr, >6 week) who were randomly assigned to receive daily supplementation of oral 0.03μgr calcitriol and to be submitted to tail suspension model. Rats were followed for 1 month and were tested for serum osteocalcin (OC), alkaline phosphatase (ALP) and serum calcium at the beginning and the end of the study period. The results were analyzed and compared between groups.

RESULTS: Although serum levels of osteocalcin and alkaline phosphatase biomarkers and total serum calcium were not significantly different within and between study groups, their levels were increased in tail suspension model compared to control group. The levels of these biomarkers were lower in those who were submitted to tail suspension model and received calcitriol supplementation compared to those who were only submitted to tail suspension (60.14 ± 11.73 ng/mL vs. 58.29 ± 2.69 ng/mL; p = 0.696 for osteocalcin and 381.86 ± 99.16 mU/mL vs. 362.57 ± 27.41 ng/mL; p = 0.635 for alkaline phosphatase).

CONCLUSION: Supplementation of daily diet with calcitriol in rats under weightlessness conditions may results in lower values for bone metabolic biomarkers of alkaline phosphatase and osteocalcin and serum calcium. This pattern of change in biomarkers of bone formation, may point to the capacity of calcitriol supplementation in preventing cellular process of osteoporosis. Thus calcitriol supplementation could be an available, economic and effective strategy for preventing bone metabolic changes related to weightlessness commonly encountered in space flight. The outcome of this study needs to be further studied in future trying to find more definite results.

Keywords: Alkaline phosphatase (ALP); Calcitriol; Osteocalcin (OC); Tail suspension model; Vitamin D

References

  1. Bone. 1998 May;22(5 Suppl):83S-88S - PubMed
  2. Ann Intern Med. 1984 Jan;100(1):1-6 - PubMed
  3. Acta Astronaut. 1995 Oct-Dec;36(8-12):463-6 - PubMed
  4. Lancet. 2007 Aug 25;370(9588):657-66 - PubMed
  5. Gravit Space Biol Bull. 2005 Jun;18(2):39-58 - PubMed
  6. J Bone Miner Res. 2003 Mar;18(3):561-9 - PubMed
  7. J Bone Miner Metab. 2002;20(4):216-22 - PubMed
  8. J Bone Miner Res. 2005 Jun;20(6):962-70 - PubMed
  9. Adv Space Biol Med. 2005;10:7-40 - PubMed
  10. J Clin Endocrinol Metab. 2001 Mar;86(3):1212-21 - PubMed
  11. Keio J Med. 2005 Jun;54(2):55-9 - PubMed
  12. J Clin Endocrinol Metab. 2013 Oct;98(10):4023-9 - PubMed
  13. Curr Osteoporos Rep. 2013 Jun;11(2):92-8 - PubMed
  14. Hepatology. 1998 Sep;28(3):695-9 - PubMed
  15. N Engl J Med. 2006 Feb 16;354(7):669-83 - PubMed
  16. PLoS One. 2013 Jun 20;8(6):e66991 - PubMed
  17. J Natl Cancer Inst. 2005 Jan 5;97(1):59-69 - PubMed
  18. Chin Med J (Engl). 2012 Nov;125(22):4093-7 - PubMed
  19. BMJ. 2010 Jan 11;340:b5664 - PubMed
  20. Endocrinol Metab Clin North Am. 1990 Mar;19(1):1-18 - PubMed
  21. Hemodial Int. 2010 Apr;14 (2):182-92 - PubMed
  22. J Appl Physiol (1985). 1999 Jun;86(6):1841-6 - PubMed
  23. J Bone Miner Res. 2013 Jun;28(6):1243-55 - PubMed
  24. J Bone Miner Res. 2005 Feb;20(2):208-18 - PubMed
  25. Br J Nutr. 2010 Oct;104(8):1091-5 - PubMed
  26. J Appl Physiol (1985). 2002 Apr;92(4):1367-77 - PubMed
  27. Aviat Space Environ Med. 1987 Jan;58(1):63-8 - PubMed
  28. Bone. 1998 May;22(5 Suppl):105S-111S - PubMed
  29. J Pharmacol Exp Ther. 1999 Oct;291(1):321-8 - PubMed
  30. Clin Endocrinol (Oxf). 2001 Feb;54(2):219-24 - PubMed
  31. Clin Rheumatol. 1995 Jul;14(4):420-4 - PubMed
  32. J Musculoskelet Neuronal Interact. 2001 Mar;1(3):193-207 - PubMed
  33. Lancet. 2000 May 6;355(9215):1607-11 - PubMed
  34. Lancet. 2000 May 6;355(9215):1569-70 - PubMed

Publication Types